Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer
Open Access
- 21 April 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (6), 680-697
- https://doi.org/10.1158/2326-6066.cir-21-0804
Abstract
Animal models are critical for the preclinical validation of cancer immunotherapies. Unfortunately, mouse breast cancer models do not faithfully reproduce the molecular subtypes and immune environment of the human disease. In particular, there are no good murine models of estrogen receptor–positive (ER+) breast cancer, the predominant subtype in patients. Here, we show that Nitroso-N-methylurea–induced mammary tumors in outbred Sprague-Dawley rats recapitulate the heterogeneity for mutational profiles, ER expression, and immune evasive mechanisms observed in human breast cancer. We demonstrate the utility of this model for preclinical studies by dissecting mechanisms of response to immunotherapy using combination TGFBR inhibition and PD-L1 blockade. Short-term treatment of early-stage tumors induced durable responses. Gene expression profiling and spatial mapping classified tumors as inflammatory and noninflammatory, and identified IFNγ, T-cell receptor (TCR), and B-cell receptor (BCR) signaling, CD74/MHC II, and epithelium-interacting CD8+ T cells as markers of response, whereas the complement system, M2 macrophage phenotype, and translation in mitochondria were associated with resistance. We found that the expression of CD74 correlated with leukocyte fraction and TCR diversity in human breast cancer. We identified a subset of rat ER+ tumors marked by expression of antigen-processing genes that had an active immune environment and responded to treatment. A gene signature characteristic of these tumors predicted disease-free survival in patients with ER+ Luminal A breast cancer and overall survival in patients with metastatic breast cancer receiving anti–PD-L1 therapy. We demonstrate the usefulness of this preclinical model for immunotherapy and suggest examination to expand immunotherapy to a subset of patients with ER+ disease. See related Spotlight by Roussos Torres, p. 672Keywords
Other Versions
Funding Information
- Driscoll and Eli Lilly (LY2157299)
- NIH (R35 CA197623, T32CA009172, P50 CA168504)
This publication has 59 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomasBreast Cancer Research, 2012
- Adenomyoepithelioma of the breast: a review stressing its propensity for malignant transformationJournal of Clinical Pathology, 2011
- Modulation of the antitumor immune response by complementNature Immunology, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Induction of mammary tumors in rat by intraperitoneal injection of NMU: histopathology and estral cycle influenceCancer Letters, 1994
- Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutationsNature, 1983